ABSTRACT
Background Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection and associated intrahost viral evolution remain unclear.
Methods Adults aged ≥18 years were enrolled at 5 hospitals and followed from 4/11/2022 – 2/1/2023. Eligible patients were SARS-CoV-2-positive in the previous 14 days and had a moderate or severely immunocompromising condition or treatment. Nasal specimens were tested by rRT-PCR every 2–4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection.
Results We enrolled 150 patients with: B cell malignancy or anti-B cell therapy (n=18), solid organ or hematopoietic stem cell transplant (SOT/HSCT) (n=59), AIDS (n=5), non-B cell malignancy (n=23), and autoimmune/autoinflammatory conditions (n=45). Thirty-eight (25%) were rRT-PCR-positive and 12 (8%) were culture-positive ≥21 days after initial SARS-CoV-2 detection or illness onset. Patients with B cell dysfunction had longer duration of rRT-PCR- positivity compared to those with autoimmune/autoinflammatory conditions (aHR 0.32, 95% CI 0.15-0.64). Consensus (>50% frequency) spike mutations were identified in 5 individuals who were rRT-PCR-positive >56 days; 61% were in the receptor-binding domain (RBD). Mutations shared by multiple individuals were rare (<5%) in global circulation.
Conclusions In this cohort, prolonged replication-competent Omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting >56 days accumulated spike mutations, which were distinct from those seen globally.
Competing Interest Statement
All authors have completed ICMJE disclosure forms (www.icmje.org/coi_disclosure.pdf). James Chappell reports receiving grants from NIH and DoD, outside the submitted work. Carlos Grijalva reports grants from NIH, CDC, AHRQ, FDA, Campbell Alliance/Syneos Health, consulting fees and participating on a DSMB for Merck, outside the submitted work. Anne Frosch reports a K08 award from NIH, and participating on the Hennepin Health Research Institute Board of Directors, outside the submitted work. Natasha Halasa reports grants from Sanofi, Quidel, and Merck, outside the submitted work. Adam Lauring reports receiving grants from CDC, NIAID, Burroughs Wellcome Fund, Flu Lab, and consulting fees from Roche, outside the submitted work. Emily Martin reports receiving a grant from Merck, outside the submitted work.
Funding Statement
Primary funding for this study was provided by the US Centers for Disease Control and Prevention (CDC) (award 75D30121F00002). Scientists from the US CDC participated in all aspects of this study, including its design, analysis, interpretation of data, writing the report, and the decision to submit the article for publication. ZR was supported by NIH T32HL007749.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This program was determined to be public health surveillance with waiver of participant informed consent by CDC and institutional review boards at all participating institutions and was conducted in accordance with applicable CDC policy and federal law.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
For the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
Email: zoraglow{at}med.umich.edu, kbz2{at}cdc.gov, jim.chappell{at}vumc.org, yuwei.zhu{at}vumc.org, etmartin{at}umich.edu, j.kwon{at}wustl.edu, anne.frosch{at}hcmed.org, ammohamed{at}montefiore.org, juliegil{at}umich.edu, bendalle{at}umich.edu, aubahr{at}umich.edu, natasha.halasa{at}vumc.org, keipp.talbot{at}vumc.org, carlos.grijalva{at}vumc.org, adrienne.baughman{at}vumc.org, kelsey.womack{at}vumc.org, cassie.johnson{at}vumc.org, sa.swan{at}vumc.org, exk0{at}cdc.gov, bwe3{at}cdc.gov, zaq6{at}cdc.gov, ibz1{at}cdc.gov, lmj9{at}cdc.gov, nax3{at}cdc.gov, wesley.self{at}vumc.org, alauring{at}med.umich.edu
Data Availability
All data produced in the present work are contained in the manuscript. Raw sequencing reads are available on the NCBI short read archive under BioProject PRJNA896930 and consensus sequences are available on GISAID.
